Effects of umbilical cord mesenchymal stem cells on expression of CYR61, FSH and AMH in mice with premature ovarian failure

The aim of this study was to objective to investigate the effects of umbilical cord mesenchymal stem cells on the expression of CYR61, FSH and AMH in mice with premature ovarian failure. For this purpose, thirty SPF female SD mice were selected as the research object, 10 of which were control group, namely group alpha, and 20 mice with premature ovarian failure model were established by cyclophosphamide. The mice were divided into model group, namely beta group and the umbilical cord mesenchymal stem cell transplantation group (gamma group), with 10 mice in each group. ELSA method was used to determine the levels of follicle-stimulating hormone (FSH), Luteinizing hormone (LH), estradiol (Estradiol) in serum. The changes of E2, Antimullerian hormone (AMH) and cysteine-rich protein 61 in ovarian tissues were determined by the protein imprinting method. Connective tissue growth factor (CTGF) and caspase-3 protein expression. Results showed that in fertility rate, gamma group > alpha group > beta group, the difference was statistically significant (P<0.05), in litter size, alpha group > gamma group > beta group, the difference was statistically significant (P<0.05). The levels of serum E2 and AMH in alpha group > gamma group > beta group, and the levels of serum FSH and LH in beta group > gamma group > alpha group were statistically significant (P<0.05). The growth follicles were alpha group > gamma group > beta group, and the atresia follicles were beta group > gamma group > alpha group, and there was a statistical difference among all groups (P<0.05). There was no difference in luteal number among the three groups (P>0.05). In terms of CYR61 and CTGF protein expression, alpha group > gamma group > beta group, and in terms of caspase-3, beta group > gamma group > alpha group had statistical significance (P<0.05). It is concluded that intervention with umbilical cord mesenchymal stem cells can significantly improve the expression levels of CYR61 and AMH, reduce the level of FSH, promote cell survival, improve the reproductive quality of mice, and restore the physiological function of the ovary. It is feasible to treat premature ovarian failure with umbilical cord mesenchymal stem cells. Copyright: (C) 2021 by the C.M.B. Association. All rights reserved.